Connect with us

Spread & Containment

Cary Institute partners on $3M USDA-funded study on COVID-19 variants that could emerge from wildlife

Many wild animals can carry COVID-19, including those that live among us, such as deer mice, red foxes, white-tailed deer, and more. These species may…

Published

on

Many wild animals can carry COVID-19, including those that live among us, such as deer mice, red foxes, white-tailed deer, and more. These species may act as reservoirs, offering new opportunities for the virus to mutate and spill back into people. The omicron variant, for example, is thought to have emerged from mice. 

Credit: Credits (clockwise from top left): NIH Image Gallery, USFWS Mountain-Prairie, La Citta Vita, and Charles J. Sharp

Many wild animals can carry COVID-19, including those that live among us, such as deer mice, red foxes, white-tailed deer, and more. These species may act as reservoirs, offering new opportunities for the virus to mutate and spill back into people. The omicron variant, for example, is thought to have emerged from mice. 

With $3 million in federal grant funding, a new five-year research project will bring together virology, disease ecology, and artificial intelligence to better understand how SARS-CoV-2 (the virus that causes COVID-19) behaves in natural ecosystems, to anticipate strains with the potential to spread widely between people and animals. The award comes from the U.S. Department of Agriculture Animal and Plant Health Inspection Service through the Ecology and Evolution of Infectious Diseases program, a joint effort of the National Institutes of Health, National Science Foundation, and the National Institute of Food and Agriculture. 

“In order to know the risk that new variants pose for people, we really have to figure out how SARS-CoV-2 is moving through mammalian wildlife,” explained Barbara Han of Cary Institute of Ecosystem Studies, who will co-lead the new project with Andrew Kramer from the University of South Florida. The project will also assess risk of spillover from people to wildlife, and how new strains could impact ecological communities.

Whereas most current disease surveillance methods collect existing variants and try to pick out the most concerning ones, the new project will use artificial intelligence to predict future variants that don’t yet exist but could be problematic if they emerge. This will generate a surveillance watch-list for the public health community.

“That way, if we find one of these in the wild, we’ll know that we should sit up and pay attention,” said Han.  

Because the strategy is proactive instead of reactive, it has the potential to shift the paradigm for how society monitors and manages SARS-CoV-2 transmission in animals, said Kramer.

The project is divided into four parts. Step 1 will use AI to create a library of future strains of SARS-CoV-2 with predicted high zoonotic potential, or the ability to infect both people and animals. In order to do this, the AI will be trained on the sequences and protein structures of past strains. 

Step 2 will predict which animals may be susceptible to the variants identified in Step 1, and therefore could serve as potential hosts. Scientists know that SARS-CoV-2 enters mammalian cells through the ACE2 receptor. However, ACE2 receptors are slightly different in every species, and haven’t been studied in the vast majority of mammals. To overcome this dearth of data, the team will use artificial intelligence to predict the structure of ACE2 receptors in various species, and whether or not the variants could bind to the receptors and infect the cell. 

Payel Das at IBM Research will lead the AI development needed for Steps 1 and 2. “IBM Research is proud to assist in the prediction of coronavirus transmission between wildlife and humans through the latest cutting-edge AI technologies, including generative AI and foundation models,” said Das. “Ultimately, we hope this work can lead to critical insights that will enable us to better prepare for future human health threats.” 

Step 3 is where the AI predictions get tested on real cells in a lab. Virologist Michael Letko of Washington State University will engineer parts of the virus strains identified in Step 1, and see if they actually bind with ACE2 receptors in cells from humans and a subset of the animals identified in Step 2. Results will be used to retrain the AI and further improve the predictions of Steps 1 and 2. 

“This part of the study is where we will move from concept to concrete,” said Letko. “Making predictions on a computer is one thing, but to actually see how those predictions perform in a physical and biological context will help us truly understand if our models are accurate.”

He added that since the experiment only uses a small piece of each virus sequence — just the part that binds with the ACE2 receptor on the outside of the cell — there is no potential for it to actually cause an infection, replicate, or spread in any way. 

In Step 4, the team will draw on 30 years of environmental monitoring at Cary Institute to simulate a Northeastern forest environment to understand how SARS-CoV-2 moves through real ecosystems where many species are differentially susceptible to infection. 

Viral outbreaks in most wild populations are under-observed, with estimations of the curves they follow mostly theoretical. By drawing on field data, the team will use models to account for how wildlife interacts in nature, where you can have multiple infected species interfacing via competition, predator-prey relationships, or other forms of contact.

“By connecting potential variants and their performance in lab assays to species interactions in the real world, we can better understand the real implications of SARS-CoV-2 being spread to many different species at the same time,” said Kramer, who will lead this portion of the study. 

Understanding these dynamics should help to improve assessments of risk to wildlife and people, and help predict spillover into humans, said Kramer — not only for SARS-CoV-2, but for other types of animal-borne diseases as well, such as avian influenza.   

The team hopes that their results will inform surveillance efforts, for example by identifying potential host species that need to be managed or by immediately sounding the alarm when one of the strains predicted to be a threat pops up in the wild.

xx

Cary Institute of Ecosystem Studies is an independent nonprofit center for environmental research. Since 1983, our scientists have been investigating the complex interactions that govern the natural world and the impacts of climate change on these systems. Our findings lead to more effective resource management, policy actions, and environmental literacy. Staff are global experts in the ecology of: cities, disease, forests, and freshwater.


Read More

Continue Reading

Spread & Containment

Dollar Tree follows Walmart and Target in bold theft-prevention move

The retailers are taking extreme steps that may be self-defeating and drive customers to Amazon, Kroger and Publix.

Published

on

Everyone thought that digital retail would eventually crush brick-and-mortar retail. 

But despite the wild success of Amazon and other online retailers, e-commerce accounted for just 14.7% of all retail sales in the second quarter of 2023.

That number was around 20% during the darkest lockdown days of the covid pandemic and it has never climbed higher than that. 

In fact, that 14.7% number has not really climbed in years because while people like the convenience of buying online, they also like the immediacy of stores.

Related: Walmart has a shady way to prevent theft Kroger, Target don't use

Next-day or even same-day delivery isn't the same as being able to shop for an item and have it instantly. In addition, some customers — maybe a lot of them — like to actually see and touch what they're buying before they make a purchase. That's certainly true in two key areas: grocery and clothing.

People want to pinch their produce and see what their meat and poultry look like before they buy. With clothing, they run the risk of an item not fitting along with them possibly not liking it, as potential reasons they might have to make a return. 

Returns ruin the convenience of shopping online. When you have to go someplace to drop off the item and then wait a day or two for the new one, going to a store clearly is easier.

Brick-and-mortar chains, however, run the risk of making their shopping experience so bad that customers opt for digital retailers.

Some changes made recently by Walmart WMT, Target and Walgreens may actually push some customers over the edge. And now the chief executive of Dollar Tree, which also owns Family Dollar, said his chain plans to copy one of the least customer-friendly moves some of its rivals have made.

Some Walgreens locations have been locking up more items.

Image source: Shutterstock

Target and Walmart lock up some items

A number of major retailers including Target, Walmart and Walgreens WBA have talked about an increase in retail theft, which the industry calls shrink. In some cases, they have taken the extreme steps of closing stores as well as locking up more items. 

That's an approach that Dollar Tree CEO Rick Dreiling, speaking during its second-quarter-earnings call, said his company would take.

"We are now taking a very defensive approach to shrink," he said. "And it's taken us a quarter, but we have several new shrink formats that we'll introduce in the back half of the year. And it goes everything from moving certain SKUs to behind the check stand. It has to do with some cases being locked up."   

Dreiling also laid out more efforts the company is making to cut down on theft.

"We have some stores that can't keep a certain SKU on the shelf just discontinuing the item. So, we have a lot of things in the works that's going to roll forward," he added.

Retail has a new big bad

Retailers have blamed their theft problems on organized retail crime. Target has been a leading proponent of pinning its theft problems on these gangs. That was how the chain justified recent store closures in Seattle, Portland, Oakland, San Francisco, and New York.

“We cannot continue operating these stores because theft and organized retail crime are threatening the safety of our team and guests, and contributing to unsustainable business performance,” Target said in a news release. 

“We know that our stores serve an important role in their communities, but we can only be successful if the working and shopping environment is safe for all."

The key question — and it's different on a market-by-market basis — is whether making the shopping experience worse to cut theft costs more than it helps. That might be true given that theft, while real, has not experienced a massive spike.

The average shrink rate in 2022 increased to 1.6% from 1.4% in 2021 and in line with shrink rates seen in 2020 and 2019, according to the National Retail Federation's latest National Retail Security Survey.

Dollar Tree may have more leeway to inconvenience its customers than Target or Walmart because it sells low-cost merchandise that's not practical to buy online. 

Still, a customer forced to wait for a clerk to buy a $1 package of toilet paper or can of soup might just opt for Kroger, Publix or the nearest neighborhood grocery chain as that type of retailer has generally not used locked shelves.

Get investment guidance from trusted portfolio managers without the management fees. Sign up for Action Alerts PLUS now.

Read More

Continue Reading

International

Novavax’s troubles continue as Covid vaccine maker plans another $300M+ in cost-cutting

Novavax, which has been reeling from a slow rollout of its Covid-19 vaccine compared to the mRNA makers, said it will once again cut costs.
Like Pfizer,…

Published

on

Novavax, which has been reeling from a slow rollout of its Covid-19 vaccine compared to the mRNA makers, said it will once again cut costs.

Like Pfizer, BioNTech and Moderna, the Gaithersburg, MD-based company is adjusting to a world in which the virus turns endemic and vaccine uptake isn’t as swift as it was in the early years of the pandemic. Now, Novavax is “prepared to initiate” more than $300 million in cost-cutting next year to “align company scope and structure with future Covid-19 market opportunity,” the company said Thursday in its third-quarter update.

Novavax slashed $950 million, or 47%, of its operating expenses in the first nine months of 2023 as revenue for the quarter fell to $187 million, down from $735 million in the same period last year.

The announcement follows a rough year for the vaccine manufacturer, which went decades without a product on the market but had its fortunes turned around during the pandemic, when it received about $1.6 billion in federal funding. To try to match the pace of its pandemic peers, Novavax grew headcount from 165 workers in 2020 to 1,992 in mid-February of this year, per SEC filings.

But with its protein-based Covid vaccine, dubbed Nuvaxovid, arriving much later than the mRNA shots after multiple delays, that meant Novavax didn’t gather as much market share and revenue. Earlier this year, it began trimming drastically, with a going-concern red flag, then $50 million in cost-cutting, followed by laying off about 25% of its staff.

John Jacobs

“With the delayed start of respiratory vaccinations, we believe we have yet to reach the midpoint of the vaccination season and, with early and encouraging signs of demand for our vaccine, we believe there remains opportunity to deliver doses and grow our share,” John Jacobs, who joined as president and CEO in January, said in a statement. “This reinforces our belief that the long-term Covid-19 market represents a sustainable opportunity for Novavax in the years to come.”

The company’s updated Covid-19 shot received FDA authorization and European Commission clearance last month. Like Moderna and Pfizer/BioNTech, it is also aiming to bring a Covid and flu combination vaccine to market. Novavax plans to start a Phase III trial of the combo shot next year, with a potential accelerated approval and launch two years later, it said Thursday. Moderna began its Phase III last month, and BioNTech said Oct. 26 that it will also enter late-stage testing “in the coming months.”

Novavax had about $666 million in cash at the end of September after a $143 million at-the-market offering last quarter.

Read More

Continue Reading

International

Novavax’s troubles continue as Covid vaccine maker plans another $300M+ in cost-cutting

Novavax, which has been reeling from a slow rollout of its Covid-19 vaccine compared to the mRNA makers, said it will once again cut costs.
Like Pfizer,…

Published

on

Novavax, which has been reeling from a slow rollout of its Covid-19 vaccine compared to the mRNA makers, said it will once again cut costs.

Like Pfizer, BioNTech and Moderna, the Gaithersburg, MD-based company is adjusting to a world in which the virus turns endemic and vaccine uptake isn’t as swift as it was in the early years of the pandemic. Now, Novavax is “prepared to initiate” more than $300 million in cost-cutting next year to “align company scope and structure with future Covid-19 market opportunity,” the company said Thursday in its third-quarter update.

Novavax slashed $950 million, or 47%, of its operating expenses in the first nine months of 2023 as revenue for the quarter fell to $187 million, down from $735 million in the same period last year.

The announcement follows a rough year for the vaccine manufacturer, which went decades without a product on the market but had its fortunes turned around during the pandemic, when it received about $1.6 billion in federal funding. To try to match the pace of its pandemic peers, Novavax grew headcount from 165 workers in 2020 to 1,992 in mid-February of this year, per SEC filings.

But with its protein-based Covid vaccine, dubbed Nuvaxovid, arriving much later than the mRNA shots after multiple delays, that meant Novavax didn’t gather as much market share and revenue. Earlier this year, it began trimming drastically, with a going-concern red flag, then $50 million in cost-cutting, followed by laying off about 25% of its staff.

John Jacobs

“With the delayed start of respiratory vaccinations, we believe we have yet to reach the midpoint of the vaccination season and, with early and encouraging signs of demand for our vaccine, we believe there remains opportunity to deliver doses and grow our share,” John Jacobs, who joined as president and CEO in January, said in a statement. “This reinforces our belief that the long-term Covid-19 market represents a sustainable opportunity for Novavax in the years to come.”

The company’s updated Covid-19 shot received FDA authorization and European Commission clearance last month. Like Moderna and Pfizer/BioNTech, it is also aiming to bring a Covid and flu combination vaccine to market. Novavax plans to start a Phase III trial of the combo shot next year, with a potential accelerated approval and launch two years later, it said Thursday. Moderna began its Phase III last month, and BioNTech said Oct. 26 that it will also enter late-stage testing “in the coming months.”

Novavax had about $666 million in cash at the end of September after a $143 million at-the-market offering last quarter.

Read More

Continue Reading

Trending